Incyte Stock News

DOHA, Qatar--(BUSINESS WIRE)--Doğuş Technology, one of Turkey's leading tech companies, will showcase its innovative, technology-driven solutions for the construction industry at ConteQ Expo 2024, alongside Doğuş Construction, at the Qatar National Convention Center from September 16-18. Both companies will present their projects that drive sector transformation by enhancing efficiency and sust...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's Retifanlimab (Zynyz) Extends Progression-Free Survival in Patients with SCAC; Data Featured at ESMO 2024 Presidential Symposium.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at ESMO Congress 2024.

Incyte Corporation reported positive results achieved from Phase 3 study using Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma. Supplemental Biologics License Application filing for label expansion of Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma, expected by end of 2024. It is expected that the 7 major follicular lymphoma ...

Incyte said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer.

WILMINGTON, Del. & WALTHAM, Mass.--(BUSINESS WIRE)---- $INCY--Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD).